{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:32:27Z","timestamp":1784327547712,"version":"3.55.0"},"reference-count":206,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Eosinophilic granulocytes are normally present in low numbers in the bloodstream. Patients with an increased number of eosinophilic granulocytes in the differential count (eosinophilia) are common and can pose a clinical challenge because conditions with eosinophilia occur in all medical specialties. The diagnostic approach must be guided by a thorough medical history, supported by specific tests to guide individualized treatment. Neoplastic (primary) eosinophilia is identified by one of several unique acquired genetic causes. In contrast, reactive (secondary) eosinophilia is associated with a cytokine stimulus in a specific disease, while idiopathic eosinophilia is a diagnosis by exclusion. Rational treatment is disease-directed in secondary cases and has paved the way for targeted treatment against the driver in primary eosinophilia, whereas idiopathic cases are treated as needed by principles in eosinophilia originating from clonal drivers. The vast majority of patients are diagnosed with secondary eosinophilia and are managed by the relevant specialty\u2014e.g., rheumatology, allergy, dermatology, gastroenterology, pulmonary medicine, hematology, or infectious disease. The overlap in symptoms and the risk of irreversible organ involvement in eosinophilia, irrespective of the cause, warrants that patients without a diagnostic clarification or who do not respond to adequate treatment should be referred to a multidisciplinary function anchored in a hematology department for evaluation. This review presents the pathophysiology, manifestations, differential diagnosis, diagnostic workup, and management of (adult) patients with eosinophilia. The purpose is to place eosinophilia in a clinical context, and therefore justify and inspire the establishment of a multidisciplinary team of experts from diagnostic and clinical specialties at the regional level to support the second opinion. The target patient population requires highly specialized laboratory analysis and therapy and occasionally has severe eosinophil-induced organ dysfunction. An added value of a centralized, clinical function is to serve as a platform for education and research to further improve the management of patients with eosinophilia. Primary and idiopathic eosinophilia are key topics in the review, which also address current research and discusses outstanding issues in the field.<\/jats:p>","DOI":"10.3389\/fonc.2023.1193730","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T06:24:11Z","timestamp":1684391051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["The multidisciplinary approach to eosinophilia"],"prefix":"10.3389","volume":"13","author":[{"given":"Gunhild Nynke","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Niemann","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Merete","family":"Lindegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper R\u00f8mhild","family":"Davidsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte Nyvang","family":"Hartmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Assing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte G.","family":"Mortz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Martin-Iguacel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Boe","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette Dr\u00f8hse","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels","family":"Havelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"El Fassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Broesby-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maiborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Lock","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen Lykkegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Weis","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4065\/80.7.923","article-title":"How to interpret and pursue an abnormal complete blood cell count in adults","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"B2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4997\/JRCPE.2014.109","article-title":"Interpretation of the full blood count in systemic disease \u2013 a guide for the physician","volume":"44","author":"Leach","year":"2014","journal-title":"J R Coll Physicians Edinb"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14488","article-title":"Guideline for the investigation and management of eosinophilia","volume":"176","author":"Butt","year":"2017","journal-title":"Br J Haematol"},{"key":"B5","unstructured":"Care program for the diagnosis and treatment of eosinophilia 3rd version2018"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26352","article-title":"World health organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/hematology.2022000367","article-title":"Approach to the patient with suspected hypereosinophilic syndrome","volume":"2022","author":"Klion","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221146938","article-title":"Eosinophilia attention, diagnosis, treatment, and awareness in physicians: a cross-sectional survey","volume":"14","author":"Chen","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183620","article-title":"Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development","volume":"12","author":"Andersen","year":"2017","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092136","article-title":"Cytokine profiling in myeloproliferative neoplasms: overview on phenotype correlation, outcome prediction, and role of genetic variants","volume":"9","author":"Masselli","year":"2020","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041906","article-title":"Inflammatory microenvironment and specific T cells in myeloproliferative neoplasms: immunopathogenesis and novel immunotherapies","volume":"22","author":"Nasillo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: a comprehensive review","volume":"2018","author":"Ramirez","year":"2018","journal-title":"BioMed Res Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-37","article-title":"Hypereosinophilic syndromes","volume":"2","author":"Roufosse","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100809","article-title":"Hypereosinophilic syndromes \u2013 an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment","volume":"49","author":"Helbig","year":"2021","journal-title":"Blood Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00441-010-1049-6","article-title":"Eosinophils in innate immunity: an evolving story","volume":"343","author":"Shamri","year":"2011","journal-title":"Cell Tissue Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020656","article-title":"Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo","volume":"195","author":"Yu","year":"2002","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","article-title":"Biology of the eosinophil","volume":"101","author":"Blanchard","year":"2009","journal-title":"Adv Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4168\/aair.2010.2.2.87","article-title":"Eosinophil survival and apoptosis in health and disease","volume":"2","author":"Park","year":"2010","journal-title":"Allergy Asthma Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000504847","article-title":"The cellular functions of eosinophils \u2013 collegium international allergologicum (CIA) update 2020","volume":"181","author":"Simon","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.14670\/HH-15.899","article-title":"Mechanisms underlying eosinophil trafficking and their relevance in vivo","volume":"15","author":"Caral","year":"2000","journal-title":"Histol Histopathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in health and disease: a state-of-the-art review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R113.546218","article-title":"Eosinophil granule proteins: form and function","volume":"289","author":"Acharya","year":"2014","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3AB0220-311R","article-title":"Galectin-10, the protein that forms charcot-Leyden crystals, is not stored in granules but resides in the peripheral cytoplasm of human eosinophils","volume":"108","author":"Melo","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246627","article-title":"Eosinophil-derived neurotoxin: a biologically and analytically attractive asthma biomarker","volume":"16","author":"Rutten","year":"2021","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e13032","DOI":"10.1111\/sji.13032","article-title":"Physiology and pathology of eosinophils: recent developments. summary of the focus workshop organized by DGAKI","volume":"93","author":"Renz","year":"2021","journal-title":"Scand J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.41.4.283","article-title":"Respiratory burst of normal human eosinophils","volume":"41","author":"Petreccia","year":"1987","journal-title":"J Leuk Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90945-1","article-title":"Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils","volume":"81","author":"Sedgwick","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432088","article-title":"Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion competent eosinophil granules in humans","volume":"121","author":"Ueki","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219048","article-title":"Characterization of the phenotype of human eosinophils and their progenitors in the bone marrow of healthy individuals","volume":"105","author":"Hassani","year":"2020","journal-title":"Haematologica"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaci.2012.12.1105","article-title":"Hypereosinophilic syndrome and thrombosis: a retrospective review","volume":"131","author":"Wallace","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19812","article-title":"Association of thrombosis with hypereosinophilic syndrome in patients with genetic alterations","volume":"4","author":"Leiva","year":"2021","journal-title":"JAMA Network Open"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111862","article-title":"Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis","volume":"9","author":"Cugno","year":"2014","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000518","article-title":"Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps","volume":"134","author":"Marx","year":"2019","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(87)90360-5","article-title":"The determination of the eosinophil count: comparison of two techniques","volume":"79","author":"Laufer","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2022.09.001","article-title":"Rethinking blood eosinophil counts: epidemiology, associated chronic diseases, and increased risks of cardiovascular disease","volume":"1","author":"Pongdee","year":"2022","journal-title":"J Allergy Clin Immunol Global"},{"key":"B48","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/ajcp\/75.5.693","article-title":"Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers","volume":"75","author":"Winkel","year":"1981","journal-title":"Am J Clin Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3343\/kjlm.2009.29.3.185","article-title":"Incidence and causes of hypereosinophilia (corrected) in the patients of a university hospital","volume":"29","author":"Kim","year":"2009","journal-title":"Korean J Lab Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"A","DOI":"10.21276\/APALM.2017.1044","article-title":"Incidence of eosinophilia in rural population in north India: a study at tertiary care hospital","volume":"4","author":"Bansal","year":"2017","journal-title":"Ann Path Lab Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099388","article-title":"Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting","volume":"9","author":"Andersen","year":"2014","journal-title":"PloS One"},{"key":"B52","article-title":"Eosinophilia detected by automated blood cell counting in ambulatory north American outpatients","volume":"121","author":"Brigden","year":"1997","journal-title":"Arch Pathol Lab Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-68-6-1220","article-title":"The hypereosinophilic syndromes","volume":"68","author":"Hardy","year":"1968","journal-title":"Ann Intern Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Med (Baltimore)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/AJCP\/AQAA056","article-title":"Contemporary classification and diagnostic evaluation of hypereosinophilia","volume":"154","author":"Mattis","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the united states and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1016\/j.jaip.2019.05.011","article-title":"Pediatric hypereosinophilia: characteristics, clinical manifestations, and diagnoses","volume":"7","author":"Burris","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3165","article-title":"Idiopathic hypereosinophilic syndrome: a rare diagnosis in children","volume":"8","author":"Pallesen","year":"2020","journal-title":"Clin Case Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.92","article-title":"Eosinophilia: a pragmatic approach to diagnosis and treatment","volume":"2015","author":"Klion","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00465.x","article-title":"Recent advances in pathogenesis and management of hypereosinophilic syndromes","volume":"59","author":"Roufosse","year":"2004","journal-title":"Allergy"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated with CD3\u2013CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/MOH.0b013e32831c841f","article-title":"Advances in diagnosis and treatment of eosinophilia","volume":"16","author":"Sheikha","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/ejh.13437","article-title":"Causes of hypereosinophilia in 100 consecutive patients","volume":"105","author":"Moller","year":"2020","journal-title":"Eur J Haematol"},{"key":"B67","first-page":"A07210558","article-title":"A retrospective cohort study of patients with eosinophilia referred to a tertiary centre","volume":"69","author":"Hougaard","year":"2022","journal-title":"Dan Med J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000803","article-title":"An approach to hypereosinophilic syndrome presenting with cutaneous features","volume":"33","author":"Fourzali","year":"2022","journal-title":"Dermatitis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.120.007405","article-title":"Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.09.023","article-title":"Eosinophilic myocarditis: characteristics, treatment, and outcomes","volume":"70","author":"Brambatti","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1148\/rg.273065051","article-title":"Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview","volume":"27","author":"Jeong","year":"2007","journal-title":"Radiographics"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2016.04.015","article-title":"Eosinophilic lung diseases","volume":"37","author":"Cottin","year":"2016","journal-title":"Clin Chest Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1183\/2312508X.erm9522","article-title":"Eosinophilic lung diseases (ERS monograph)","author":"Jackson","year":"2022","journal-title":"Sheffield Eur Resp Soc"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.12.004","article-title":"Churg-Strauss syndrome","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European Position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B77","first-page":"A4235","article-title":"The sino-nasal outcome test 22 validated for Danish patients","volume":"58","author":"Lange","year":"2011","journal-title":"Dan Med Bull"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30005-0","article-title":"Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus","volume":"3","author":"Walker","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B79","article-title":"Neurologic manifestations of hypereosinophilic syndrome\u2013review of the literature","volume":"51","author":"Titli\u0107","year":"2012","journal-title":"Acta Clin Croat"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.10.023","article-title":"Central nervous system involvement of hypereosinophilic syndrome: a report of 10 cases and a literature review","volume":"347","author":"Lee","year":"2014","journal-title":"J Neurol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120529","article-title":"Eosinophilia and kidney disease: more than just an incidental finding","volume":"7","author":"Gauckler","year":"2018","journal-title":"J Clin Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102626","article-title":"Clinicopathological characteristics and outcomes of eosinophilic cystitis: a retrospective study","volume":"68","author":"Hasan","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.02.016","article-title":"Eosinophilia associated with immune deficiency","volume":"10","author":"Olbrich","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2021.08.008","article-title":"Allergology international 2021. inborn errors of immunity with eosinophilia","volume":"70","author":"Okamoto","year":"2021","journal-title":"Allergology Int"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3850","article-title":"Familial eosinophilia: a benign disorder","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/all.13146","article-title":"Dysregulation of interleukin 5 expression in familial eosinophilia","volume":"72","author":"Babu","year":"2017","journal-title":"Allergy"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2012.05.004","article-title":"Eosinophilia in the returning traveler","volume":"26","author":"Ustianowski","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"B88","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.iac.2015.05.003","article-title":"Eosinophilia in infectious diseases","volume":"35","author":"O\u2019Connell","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5845","article-title":"Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome","volume":"6","author":"Andersen","year":"2015","journal-title":"Oncotarget"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2459.bloodjournal8762459","article-title":"The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (aml m4eo) and carry the pericentric inversion 16: a combination of may-Gr\u00fcnwald-Giemsa staining and fluorescence in situ hybridization","volume":"87","author":"Haferlach","year":"1996","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.blre.2019.03.007","article-title":"Eosinophilia in acute myeloid leukemia: overlooked and underexamined","volume":"36","author":"Naymagon","year":"2019","journal-title":"Blood Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01374","article-title":"B-ALL with t(5;14)(q31;q32); IGH-IL3 rearrangement and eosinophilia: a comprehensive analysis of a peculiar IGH-rearranged b-ALL","volume":"9","author":"Fournier","year":"2019","journal-title":"Front Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.17179\/excli2021-4462","article-title":"The eosinophilic variant of chronic myeloid leukemia","volume":"20","author":"Langabeer","year":"2021","journal-title":"EXCLI J"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02220","article-title":"Involvement and possible role of eosinophils in asthma exacerbation","volume":"9","author":"Nakagome","year":"2018","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4065\/75.6.586","article-title":"Peripheral blood eosinophilia in association with sarcoidosis","volume":"75","author":"Renston","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"B98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","volume":"15","author":"Chen","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","article-title":"IgE, mast cells, and eosinophils in atopic dermatitis","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205526","article-title":"IgG4-related disease: what a hematologist needs to know","volume":"104","author":"Chen","year":"2019","journal-title":"Haematologica"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983812","article-title":"Eosinophils in filarial infections: inducers of protection or pathology","volume":"13","author":"Ehrens","year":"2022","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.10.005","article-title":"Hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis and other eosinophilic lung diseases","volume":"66","author":"Barry","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.08.033","article-title":"Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature","volume":"50","author":"Roberts","year":"2005","journal-title":"J Infect"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091264","article-title":"Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder","volume":"100","author":"Khoury","year":"2015","journal-title":"Haematologica"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13710","article-title":"Enhanced activation of eosinophils in peripheral blood and implications for eosinophilic esophagitis diagnosis","volume":"32","author":"Botan","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761718","article-title":"High prevalence of myeloid neoplasms in adults with non-langerhans cell histiocytosis","volume":"130","author":"Papo","year":"2017","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/his.14718","article-title":"Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia","volume":"81","author":"Tsuyama","year":"2022","journal-title":"Histopathology"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013338","article-title":"ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition","volume":"139","author":"Kemps","year":"2022","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPARC3YQ0KLIOA","article-title":"A subset of rosai-dorfman disease exhibits features of IgG4-related disease","volume":"139","author":"Zhang","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.049","article-title":"Mepolizumab-responsive kimura disease","volume":"9","author":"Kinoshita","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B113","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12885-020-06966-3","article-title":"Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis","volume":"20","author":"Hu","year":"2020","journal-title":"BMC Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","article-title":"Eosinophils and cancer","volume":"2","author":"Davis","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.11.022","article-title":"A retrospective review of 193 cases of severe eosinophilia in the northeast united states","volume":"134","author":"Lam","year":"2021","journal-title":"Am J Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"AB66","DOI":"10.1016\/j.jaci.2019.12.731","article-title":"The etiology of severe eosinophilia in hospitalized patients","volume":"145","author":"Tal","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024328","article-title":"Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy","volume":"100","author":"Yang","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639395","article-title":"Hypereosinophilia in solid tumors{{\/amp]]mdash; case report and clinical review","volume":"11","author":"Zalewska","year":"2021","journal-title":"Front Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","article-title":"A new dawn for eosinophils in the tumour microenvironment","volume":"20","author":"Grisaru-Tal","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092294","article-title":"Blood eosinophils are associated with efficacy of targeted therapy in patients with advanced melanoma","volume":"14","author":"Wendlinger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.017","article-title":"Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies","volume":"81","author":"Bernard-Tessier","year":"2017","journal-title":"Eur J Cancer"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1727116","article-title":"Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors","volume":"9","author":"Simona","year":"2020","journal-title":"Oncoimmunology"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16266","article-title":"Elevated eosinophil count following pembrolizumab treatment for non-small cell lung cancer","volume":"13","author":"Baroz","year":"2021","journal-title":"Cureus"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1722022","article-title":"Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database","volume":"9","author":"Scanvion","year":"2020","journal-title":"Oncoimmunology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061243","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system","volume":"18","author":"Cho","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B126","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s13671-021-00348-z","article-title":"Updates and insights in the diagnosis and management of DRESS syndrome","volume":"10","author":"Schunkert","year":"2021","journal-title":"Curr Dermatol Rep"},{"key":"B127","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1172\/JCI110024","article-title":"Effects of corticosteroids on eosinophil chemotaxis and adherence","volume":"67","author":"Altman","year":"1981","journal-title":"J Clin Invest"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.147.10.3490","article-title":"Glucocorticoids inhibit cytokine-mediated eosinophil survival","volume":"147","author":"Wallen","year":"1991","journal-title":"J Immunol"},{"key":"B129","article-title":"Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils","volume":"75","author":"Hallsworth","year":"1992","journal-title":"Immunology"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90333-6","article-title":"The effects of glucocorticoids on human eosinophils","volume":"94","author":"Schleimer","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu427","article-title":"Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis","volume":"54","author":"Grayson","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00055-2016","article-title":"Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease","volume":"47","author":"Pavord","year":"","journal-title":"Eur Respir J"},{"key":"B133","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/annonc\/8.suppl_2.S89","article-title":"The role of eosinophils in the pathobiology of hodgkin's disease","volume":"8","author":"Pinto","year":"1997","journal-title":"Ann Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa208","article-title":"Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2","volume":"155","author":"Pozdnyakova","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/S2152-2650(22)01466-5","article-title":"MPN-521 somatic mutational landscape and clinical response to upfront targeted tyrosine kinase inhibitors among patients with myeloid and lymphoid neoplasms with eosinophilia and rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3","author":"Zhang","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0042","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021","volume":"18","author":"Gerds","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1\u2013PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2021.100279","article-title":"Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: case report and literature review","volume":"16","author":"Singh","year":"2021","journal-title":"Leuk Res Rep"},{"key":"B144","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ajcp\/aqaa244","article-title":"Eosinophilia\/hypereosinophilia in the setting of reactive and idiopathic causes, well-defined myeloid or lymphoid leukemias, or germline disorders","volume":"155","author":"Kelemen","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07893.x","article-title":"A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes","volume":"147","author":"Intermesoli","year":"2009","journal-title":"Br J Haematol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e318169569a","article-title":"Successful treatment of hypereosinophilic syndrome with cyclosporine","volume":"337","author":"Donald","year":"2009","journal-title":"Am J Med Sci"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.2174\/138945011794815211","article-title":"Interferon treatment in patients with hypereosinophilia","volume":"12","author":"Bjerrum","year":"2011","journal-title":"Curr Drug Targets"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.04.033","article-title":"Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome","volume":"16","author":"Tabata","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical profile and treatment in hypereosinophilic syndrome variants: a pragmatic review","volume":"10","author":"Requena","year":"2022","journal-title":"J Allergy Clin Immunol: In Pract"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1425142","article-title":"Imatinib for the treatment of hypereosinophilic syndromes","volume":"14","author":"Helbig","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.anai.2019.10.016","article-title":"Asthma biologics: comparing trial designs, patient cohorts and study results","volume":"124","author":"Doroudchi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08749-6","article-title":"Eosinophilic esophagitis: the potential role of biologics in its treatment","volume":"59","author":"Choudhury","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12325-022-02307-x","article-title":"A review of anti-IL-5 therapies for eosinophilic granulomatosis with polyangiitis","volume":"40","author":"Katsuno","year":"2023","journal-title":"Adv Ther"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000352","article-title":"Reducing bureaucracy in clinical research: a call for action","volume":"4","author":"Gribben","year":"2020","journal-title":"Hemasphere"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01308","article-title":"Hematological malignancy specific patient-reported outcome measure (HM-PRO): construct validity study","volume":"11","author":"Goswami","year":"2020","journal-title":"Front Pharmacol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","article-title":"Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials","volume":"59","author":"Gwaltney","year":"2017","journal-title":"Leuk Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1480768","article-title":"Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life","volume":"60","author":"Langlais","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00448-8","article-title":"Quality of life research within the EORTC-the EORTC QLQ-C30. European organisation for research and treatment of cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02688-y","article-title":"Psychometric properties of the EQ-5D-5L: a systematic review of the literature","volume":"30","author":"Feng","year":"2021","journal-title":"Qual Life Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2341","article-title":"Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative","volume":"25","author":"Garcia","year":"2007","journal-title":"J Clin Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5967","article-title":"Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1179\/jmt.2009.17.3.163","article-title":"Global rating of change scales: a review of strengths and weaknesses and considerations for design","volume":"17","author":"Kamper","year":"2009","journal-title":"J Man Manip Ther"},{"key":"B169","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa383","article-title":"Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties","volume":"59","author":"Chessa","year":"2020","journal-title":"Rheumatology"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1125-1","article-title":"A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms","volume":"25","author":"Brochmann","year":"2016","journal-title":"Qual Life Res"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.4103\/2152-7806.139612","article-title":"Multidisciplinary in\u2212hospital teams improve patient outcomes: a review","volume":"5","author":"Epstein","year":"2014","journal-title":"Surg Neurol Int"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00136","article-title":"The role of an integrated multidisciplinary clinic in the management of patients with cutaneous lymphoma","volume":"5","author":"Tyler","year":"2015","journal-title":"Front Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00039-2016","article-title":"A multidisciplinary team case management approach reduces the burden of frequent asthma admissions","volume":"2","author":"Burke","year":"2016","journal-title":"ERJ Open Res"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00085","article-title":"The multidisciplinary team (MDT) approach and quality of care","volume":"10","author":"Taberna","year":"2020","journal-title":"Front Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrab044","article-title":"A systematic review of colorectal multidisciplinary team meetings: an international comparison","volume":"5","author":"Fehervari","year":"2021","journal-title":"BJS Open"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.857699","article-title":"The role of a longitudinal, multidisciplinary clinic in building a unique research collaborative","volume":"12","author":"Gonzales","year":"2022","journal-title":"Front Oncol"},{"key":"B178","first-page":"V01180032","article-title":"Eosinophilia","volume":"180","author":"Bjerrum","year":"2018","journal-title":"Ugeskr Laeger"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s11042-022-12402-4","article-title":"Virtual conference design: features and obstacles","volume":"81","author":"Hurst","year":"2022","journal-title":"Multimed Tools Appl"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13279","article-title":"Multidisciplinary approach to the management of adult eosinophilic oesophagitis in the united kingdom","volume":"48","author":"Hunter","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"B181","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2500\/aap.2022.43.210102","article-title":"Outcomes of eosinophilic esophagitis in patients managed in a multidisciplinary clinic","volume":"43","author":"McMurray","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.970446","article-title":"Case report: different clinical manifestations of the rare loeffler endocarditis","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17264","article-title":"Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival","volume":"192","author":"Egholm","year":"2021","journal-title":"Br J Haematol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-330845","article-title":"The expanding role(s) of eosinophils in health and disease","volume":"120","author":"Jacobsen","year":"2012","journal-title":"Blood"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"key":"B186","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-093019-125918","article-title":"Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies","volume":"39","author":"Jacobsen","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2015.07.004","article-title":"Eosinophilic myocarditis without hypereosinophilia accompanied by giant cell infiltration","volume":"12","author":"Sugiyama","year":"2015","journal-title":"J Cardiol cases"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137075","article-title":"Emerging evidence for pleiotropism of eosinophils","volume":"22","author":"Rodrigo-Mu\u00f1oz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B190","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1053\/j.semnuclmed.2017.10.003","article-title":"Currently available radiopharmaceuticals for imaging infection and the holy grail","volume":"48","author":"Salmanoglu","year":"2018","journal-title":"Semin Nucl Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010019","article-title":"Discovery, function, and therapeutic targeting of siglec-8","volume":"10","author":"Youngblood","year":"2020","journal-title":"Cells"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.7150\/ntno.50721","article-title":"Non-radioactive and sensitive tracking of neutrophils towards inflammation using antibody functionalized magnetic particle imaging tracers","volume":"5","author":"Chandrasekharan","year":"2021","journal-title":"Nanotheranostics"},{"key":"B194","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V58.5.1012.1012","article-title":"A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. i. hematologic manifestations","volume":"58","author":"Flaum","year":"1981","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V58.5.1021.1021","article-title":"A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. clinical manifestations","volume":"58","author":"Schooley","year":"1981","journal-title":"Blood"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206344","article-title":"Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion","volume":"13","author":"Rios-Navarro","year":"2018","journal-title":"PloS One"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2019.06.015","article-title":"Association of the blood eosinophil count with end-organ symptoms","volume":"45","author":"Bjerrum","year":"2019","journal-title":"Ann Med Surg (Lond)"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02808-7","article-title":"Acute hypereosinophilia in emergency department: variables associated with a 3\u2212month mortality","volume":"17","author":"Baisse","year":"2022","journal-title":"Intern Emerg Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03031","article-title":"Severe eosinophilia in myelodysplastic syndrome with a defined and rare cytogenetic abnormality","volume":"9","author":"Rai","year":"2018","journal-title":"Front Immunol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223044","article-title":"Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities","volume":"82","author":"Berti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11899-018-0448-8","article-title":"Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes","volume":"13","author":"Dispenza","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020486","article-title":"Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes","volume":"22","author":"Stella","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell associated conditions","volume":"135","author":"Kiwamotoa","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B205","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.jaci.2018.10.066","article-title":"Siglec-8 in eosinophilic disorders: receptor expression and targeting using chimeric antibodies","volume":"143","author":"Legrand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B206","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1016\/j.jaip.2020.04.069","article-title":"Symptom assessment in hypereosinophilic syndrome: toward development of a patient-reported outcomes tool","volume":"8","author":"Kovacs","year":"2020","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1193730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T06:24:21Z","timestamp":1684391061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1193730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":206,"alternative-id":["10.3389\/fonc.2023.1193730"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1193730","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"article-number":"1193730"}}